Kelly, CP, Pothoulakins, C, LaMont, JT. Clostridium difficile colitis. N Engl J Med 1994;330:257–262.
Barbut, F, Petit, JC. Epidemiology of Clostridium difficile-associated infection. Clin Microbiol infect 2001;7:405–441.
Thorpe, CM, Gorbach, SL. Update on Clostridium difficile. Curr Treat Options Gastroenterol 2006;9:265–271.
Al-Tureihi, FI, Hassoun, A, Wolf-Klein, G, et al. Length of stay, and proton pump inhibitors: Key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105–108.
Spencer, RC. Clinical impact and associated costs of Clostridium difficle-associated disease. J Antimicrob Chemother 1998;41(Suppl):C5–C12.
Schroeder, MS. Clostridium difficile-associated diarrhea. Am Fam Physician 2005;71:921–928.
Kyne, L, Hamel, MB, Polavaram, R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
Al-Eidan, FA, McElnay, JC, Scott, MG, et al. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther 2000;25:101–109.
Pepin, J, Saheb, N, Coulombe, MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
Thomas, C, Stevenson, M, Riley, TV. Antibiotics and hospital-acquired Clostridium difficle-associated diarrhea: A systemic review. J Antimicrob Chemother 2003;51:1339–1350.
Wistrom, J, Norrby, SR, Myhre, EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. J Antimicrob Chemother 2001;47:43–50.
Bignardi, GE. Risk for Clostridium difficile infection. J Hosp Infect 1998;40:1–15.
de Lalla, F, Privitera, G, Ortisi, G, et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: A four-year survey in a general hospital. J Antimicrob Chemother 1989;23:623–631.
Levy, DG, Stergachis, A, McFarland, LV, et al. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91–102.
Johnson, S, Clabots, CR, Linn, FV, et al. Nosocomial Clostridium colonization and disease. Lancet 1990;336:97–100.
Dial, S, Delaney, JA, Barkun, AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;21:2989–2995.
Yearsley, KA, Gilby, LJ, Ramadas, AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613–619.
Cunningham, R, Dale, B, Undy, B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003;54:243–245.
Dial, S, Alrasadi, K, Manoukian, C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004;171:33–38.
CAG News. Clostridium difficile-associated diarrhea (CDAD) and proton pump inhibitor therapy: CAG Position Statement. Can J Gastroenterol 2005;19:1–3.
Nawaz, A, Mohammed, I, Ahsan, K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998;93:1175–1176.
Shah, S, Lewis, A, Leopold, D, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175–181.
Lowe, DO, Mamdani, MM, Kopp, A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: A population-based study. Clin Infect Dis 2006;15:1272–1276.
Dial, S, Delaney, JA, Schneider, V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175:745–748.
Wilson, KH, Sheagren, JN, Freter, R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hampster. J Infect Dis 1985;151:355–361.
Parente, F, Cucino, C, Gallus, S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: A 1-month survey. Aliment Pharmacol Ther 2003;17:1503–1506.
Westbrook, JI, Duggan, AE, McIntosh, JH. Prescriptions for antiulcer drugs in Australia: volume, trends, and costs. BMJ 2001;323:1338–1339.
Kaatz, GW, Gitlin, SD, Schaberg, DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988;127:1289–1294.
Privitera, G, Scarpellini, P, Ortisi, G. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991;35:208–210.
K/DOQI. Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. National Guideline Clearinghouse. Available at: http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=3192. Accessed on September 24, 2006.
Dupont, WD. Power calculation for matched case-control studies. Biometrics 1998;44:1157–1168.
Garson, G David (n.d.). Log-Linear, logit, and probit models: Conditional logit models, from statnotes: Topics in multivariate analysis. Available at: http://www2.chass.ncsu.edu/garson/pa765/statnote.htm. Accessed on March 26, 2007.
Greenland, S, Schwartzbaum, JA, Finkle, WD, et al. Problem due to small samples and spares data in conditional logistic regression analysis. Am J Epidemiol 2000;151:531–539.
Cytel Statistical Software & Services. LogXact 7 with cytel studio: Discrete regression software featuring exact methods, user manual. Cambridge, MA 2005:223.
Pham, CQ, Regal, RE, Bostwick, TR, et al. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006;40:1261–1266.
Nardino, RJ, Vender, RJ, Herbert, PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118–3122.
Arthur Grube, RR, Byron May, D. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007;64:1396–1400.